Metabotrophic glutamate receptor 5 modulators and methods use thereof

• US 10,640,510 B2
• Filed: 12/06/2018
• Issued: 05/05/2020
• Est. Priority Date: 06/08/2011
• Status: Active Grant

• Current Assignee: Sunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
• Original Assignee: Sunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
• Inventors: Heffernan, Michele L. R., Hardy, Larry Wendell, Wu, Frank Xinhe, Saraswat, Lakshmi D., Spear, Kerry L.
• Primary Examiner(s): Bernhardt, Emily A
• Assistant Examiner(s): Daniel, Laura M
• Application Number:
  US16/211,338
• Publication Number:
  US 20190135815A1
• Time in Patent Office: Days
• Field of Search: None
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 471/14 Ortho-condensed systems
• CPC Class Codes: C07D 471/20 Spiro-condensed systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/10 Spiro-condensed systems
• CPC Class Codes: C07D 487/14 Ortho-condensed systems
• CPC Class Codes: C07D 487/18 Bridged systems
• CPC Class Codes: C07D 491/147 the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
• CPC Class Codes: C07D 491/20 Spiro-condensed systems
• CPC Class Codes: C07D 491/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C07D 498/04 Ortho-condensed systems

Abstract

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Claims

1. A compound, wherein said compound is:

2. The compound according to claim 1, wherein said compound is:

3. The compound according to claim 1, wherein said compound is:

4. A method of treating Fragile X, comprising the step of administering the compound:

5. The method according to claim 4, wherein said compound is:

6. The method according to claim 4, wherein said compound is: